The pill called orfoglipron – developed for the treatment of diabetes, overweight and other symptoms – is currently included in several studies conducted by Eli Lilly. In the study now being presented, it has been compared to the results of using the Danish competitor Novo Nordisk's Ozempic injectors.
The trials presented show that patients who used the pill for a period of time lost 7.9 percent of their body weight, while those who used Ozempic injectors lost 6 percent.
Blood sugar levels were also reduced for patients by an average of 1.3 percent, which can be compared to 2.1 percent for those who used Ozempic.
